Ardena
↗Ghent, Belgium
Ardena is a leading multi-service Contract Development and Manufacturing Organization (CDMO) that provides integrated drug development services. The company assists biopharmaceutical companies in navigating the complexities of drug discovery and development, offering a 'Make, Analyze, File' model that spans from early-stage chemistry to clinical supply.
Ardena specializes in small molecules and is a recognized leader in nanomedicine drug delivery systems. Their services include solid-state research, API development, formulation development, bioanalytical services, and CMC regulatory support. With a strong focus on precision medicine, they support over 600 active programs for a global client base.
CLASSIFICATION
SIZE & FINANCIALS
Employees:501-1000
Revenue:$50M-$100M
Founded:2017
Ownership:private
Status:operating
FUNDING
Stage:Private Equity
Total Raised:$100M+
Investors:GHO Capital Partners, Mentha Capital (Previous)
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial (Service Provider)
Modalities:Small molecule, Nanomedicines, Lipid Nanoparticles (LNP), Liposomes, Peptides, Oligonucleotides
Active Trials:600
Trial Phases:Phase 1: 200 | Phase 2: 150 | Phase 3: 50 | Phase 4: 10
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:ChemConnection, Syntagon, Idifarma, Crystallics
Key Partnerships:Nouveau Biosciences (Nanomedicine production), Peptinovo Biopharma (Cancer nanotherapy manufacturing)
COMPETITION
Position:Leader
Competitors:Lonza, Catalent, Recipharm, Almac Group, Eurofins, Siegfried
LEADERSHIP
Key Executives:
Jeremie Trochu - CEO
Harry Christiaens - Former CEO / Board Member
Dipesh Patel - Chief Quality Officer
Scientific Founders:Gerjan Kemperman
Board Members:Jeremie Trochu, Gijs Botman
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Ardena. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.